Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company focused on developing CD19 and CD22-targeted Artemis T-cell therapies for cancer and autoimmune diseases, has announced the successful dosing of the first patient in the dose-expansion phase of its ongoing STARLIGHT-1 Phase 1/2 clinical trial evaluating EB103 in patients with Relapsed/Refractory (R/R) B-cell Non-Hodgkin’s Lymphoma (NHL).

The milestone follows encouraging efficacy results from the dose-escalation phase of the study. At the six-month assessment, all evaluable Phase 1 patients without central nervous system (CNS) involvement who achieved a complete response continued to remain in complete remission.

Commenting on the development, Cheng Liu, Ph.D., Chief Executive Officer of Estrella Immunopharma, said, “This marks an important milestone for Estrella and STARLIGHT-1. The sustained complete responses observed to date reinforce EB103’s potential to deliver best-in-class outcomes for patients with R/R B-cell NHL. We remain deeply committed to advancing EB103.”

The dose-expansion phase is being conducted as a multi-centre, open-label study to further assess the safety and efficacy of EB103 at the recommended Phase 2 dose (RP2D) in adult patients with relapsed or refractory B-cell NHL. Data generated from this cohort will support the development of the pivotal trial strategy for the investigational therapy.

The trial is currently active at multiple research centres, including UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute.

Estrella continues to advance its pipeline of Artemis T-cell therapies as it seeks to develop innovative treatment options for patients with cancer and autoimmune diseases.